Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -8% Improvement Relative Risk Progression -4% Progression (b) 2% c19early.org/o Eikelboom et al. NCT04324463 ACT inpatient Colchicine RCT LATE Favors colchicine Favors control
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Eikelboom et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00298-3, ACT inpatient, NCT04324463 (history)
10 Oct 2022    Source   PDF   Share   Tweet
RCT very late stage (baseline SpO2 80%) patients, showing no significant differences with colchicine treatment.
risk of death, 8.0% higher, HR 1.08, p = 0.38, treatment 264 of 1,304 (20.2%), control 249 of 1,307 (19.1%).
risk of progression, 4.0% higher, HR 1.04, p = 0.58, treatment 368 of 1,304 (28.2%), control 356 of 1,307 (27.2%), high-flow oxygen, ventilation, or death.
risk of progression, 2.0% lower, HR 0.98, p = 0.84, treatment 246 of 1,304 (18.9%), control 252 of 1,307 (19.3%), NNT 241, high-flow oxygen or ventilation.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Eikelboom et al., 10 Oct 2022, Randomized Controlled Trial, multiple countries, peer-reviewed, mean age 56.0, 29 authors, study period 2 October, 2020 - 10 February, 2022, average treatment delay 7.0 days, dosage 1.8mg day 1, 1.2mg days 2-28, trial NCT04324463 (history) (ACT inpatient).
Contact: eikelbj@mcmaster.ca.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit